The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals Up Nearly 6%, on Pace for Largest Percent Increase Since December 2023 — Data Talk Vertex Pharmaceuticals Incorporated (VRTX) is currently at $464.17, up $25.77 or 5.88% --Would ...

Life Science Washington, the state’s life sciences industry association, today announced the expansion of its board of directors with the addition of nine new members, representing distinguished ...

The FDA approves a new type of nonopioid painkiller for acute pain. And NBC News speaks to transgender service members who ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

BURLINGTON, Mass. - Azenta, Inc. (NASDAQ: AZTA), a global provider of life sciences solutions, announced the election of ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates, today announced it has successfully completed ...